Reply to "Drug Susceptibility of Genetically Engineered Trypanosoma cruzi Strains and Sterile Cure in Animal Models as a Criterion for Potential Clinical Efficacy of Anti-T. cruzi Drugs"

Antimicrob Agents Chemother. 2015 Dec;59(12):7925. doi: 10.1128/AAC.02022-15.

Authors

Amanda Fortes Francisco¹, Michael D Lewis¹, Shiromani Jayawardhana¹, Martin C Taylor¹, Eric Chatelain², John M Kelly³

Affiliations

¹ Department of Pathogen Molecular Biology, London School of Hygiene and Tropical Medicine, London, United Kingdom.
² Drugs for Neglected Diseases Initiative (DNDi), Geneva, Switzerland.
³ Department of Pathogen Molecular Biology, London School of Hygiene and Tropical Medicine, London, United Kingdom john.kelly@lshtm.ac.uk.

No abstract available

Publication types

Letter
Comment

MeSH terms

Animals
Antifungal Agents / pharmacology*
Chagas Disease / drug therapy*
Chronic Disease / drug therapy*
Female
Triazoles / pharmacology*
Trypanocidal Agents / pharmacology*
Trypanosoma cruzi / drug effects*

Substances

Antifungal Agents
Triazoles
Trypanocidal Agents